Zoetis Inc. (ZTS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 9.05B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | 0.00 USD | Commercial Paper |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 15.08B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $9.05B | $0.00 | (m) | $15.08B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $9.04B | $0.00 | (m) | $15.15B | (m) |
| 2025-12-31 | $9.04B | (m) | $0.00 | $9.04B | $0.00 | (m) | $15.47B | 58.46% |
| 2025-09-30 | $7.07B | (m) | $0.00 | $7.07B | $0.00 | (m) | $15.16B | 46.63% |
| 2025-06-30 | $6.58B | (m) | $1.35B | $5.23B | $0.00 | (m) | $14.48B | 45.45% |
| 2025-03-31 | $6.58B | (m) | $1.35B | $5.23B | $0.00 | (m) | $14.10B | 46.65% |
| 2024-12-31 | $6.57B | (m) | $1.35B | $5.22B | $0.00 | (m) | $14.24B | 46.15% |
| 2024-09-30 | (m) | (m) | (m) | $6.57B | $0.00 | (m) | $14.36B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $6.56B | $0.00 | (m) | $14.16B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $6.56B | $0.00 | (m) | $14.35B | (m) |
| 2023-12-31 | $6.56B | (m) | $0.00 | $6.56B | $0.00 | (m) | $14.29B | 45.95% |
| 2023-09-30 | $6.55B | (m) | $0.00 | $6.55B | $0.00 | (m) | $14.11B | 46.45% |
| 2023-06-30 | $6.55B | (m) | $0.00 | $6.55B | $0.00 | (m) | $13.75B | 47.68% |
| 2023-03-31 | $6.56B | (m) | $0.00 | $6.56B | $0.00 | (m) | $13.75B | 47.69% |
| 2022-12-31 | $7.90B | (m) | $1.35B | $6.55B | $0.00 | (m) | $14.93B | 52.94% |
| 2022-09-30 | $6.56B | (m) | $1.35B | $5.21B | $0.00 | (m) | $13.67B | 47.97% |
| 2022-06-30 | $6.57B | (m) | $1.35B | $5.22B | $0.00 | (m) | $13.77B | 47.72% |
| 2022-03-31 | $6.58B | (m) | $1.35B | $5.23B | $0.00 | (m) | $13.86B | 47.46% |
| 2021-12-31 | $6.59B | (m) | $0.00 | $6.59B | $0.00 | (m) | $13.90B | 47.42% |
| 2021-09-30 | $6.59B | (m) | $0.00 | $6.59B | $0.00 | (m) | $13.71B | 48.10% |
| 2021-06-30 | $7.19B | (m) | $600.00M | $6.59B | $0.00 | (m) | $14.07B | 51.12% |
| 2021-03-31 | $7.19B | (m) | $600.00M | $6.59B | $0.00 | (m) | $13.80B | 52.09% |
| 2020-12-31 | $7.20B | (m) | $600.00M | $6.59B | $0.00 | (m) | $13.61B | 52.87% |
| 2020-09-30 | $7.70B | (m) | $1.10B | $6.59B | $0.00 | (m) | $13.72B | 56.07% |
| 2020-06-30 | $7.70B | (m) | $500.00M | $7.19B | $1.50M | (m) | $13.07B | 58.88% |
| 2020-03-31 | $6.46B | (m) | $500.00M | $5.96B | $0.00 | (m) | $11.53B | 56.06% |
| 2019-12-31 | $6.45B | (m) | $500.00M | $5.95B | $0.00 | (m) | $11.54B | 55.84% |
| 2019-09-30 | (m) | (m) | (m) | $6.45B | $0.00 | (m) | $11.27B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $6.45B | $0.00 | (m) | $10.99B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $6.44B | $0.00 | (m) | $10.88B | (m) |
| 2018-12-31 | $6.44B | (m) | $0.00 | $6.44B | $0.00 | (m) | $10.78B | 59.78% |
| 2018-09-30 | (m) | (m) | (m) | $6.44B | $0.00 | (m) | $10.46B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $4.96B | $0.00 | (m) | $8.60B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $4.95B | $0.00 | (m) | $8.69B | (m) |
| 2017-12-31 | $4.95B | (m) | $0.00 | $4.95B | $0.00 | (m) | $8.59B | 57.69% |
| 2017-10-01 | (m) | (m) | $750.00M | $4.95B | (m) | (m) | $9.29B | (m) |
| 2017-07-02 | (m) | (m) | $750.00M | $3.72B | (m) | (m) | $7.80B | (m) |
| 2017-04-02 | $4.47B | (m) | $750.00M | $3.72B | $0.00 | (m) | $7.65B | 58.41% |
| 2016-12-31 | $4.47B | (m) | $0.00 | $4.47B | $0.00 | (m) | $7.65B | 58.41% |
| 2016-10-02 | $4.47B | (m) | $0.00 | $4.47B | $0.00 | (m) | $7.71B | 57.90% |
| 2016-07-03 | $4.46B | (m) | $0.00 | $4.46B | $0.00 | (m) | $7.52B | 59.39% |
| 2016-04-03 | $4.46B | (m) | $0.00 | $4.46B | $0.00 | (m) | $7.45B | 59.90% |
| 2015-12-31 | $4.86B | (m) | $400.00M | $4.46B | $0.00 | (m) | $7.91B | 61.46% |
| 2015-09-27 | $3.63B | (m) | $400.00M | $3.23B | $0.00 | (m) | $6.69B | 54.23% |
| 2015-06-28 | $3.64B | (m) | $400.00M | $3.24B | $0.00 | (m) | $6.60B | 55.21% |
| 2015-03-29 | $3.64B | (m) | $400.00M | $3.24B | $0.00 | (m) | $6.43B | 56.66% |
| 2014-12-31 | (m) | (m) | (m) | $3.64B | (m) | (m) | $6.61B | (m) |
| 2014-09-28 | (m) | (m) | (m) | $3.64B | $0.00 | (m) | $6.53B | (m) |
| 2014-06-29 | (m) | (m) | (m) | $3.64B | $0.00 | (m) | $6.52B | (m) |
| 2014-03-30 | (m) | (m) | (m) | $3.64B | (m) | (m) | $6.40B | (m) |
| 2013-12-31 | (m) | (m) | (m) | $3.64B | $0.00 | (m) | $6.56B | (m) |
| 2013-09-29 | (m) | (m) | (m) | $3.64B | $0.00 | (m) | $6.26B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $3.64B | $0.00 | (m) | $6.26B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $3.64B | (m) | (m) | $6.14B | (m) |
| 2012-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $6.26B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |